Sanofi’s Aubagio And Biogen Idec’s Tecfidera Make It A Good Day For MS Sufferers At EMA

The EMA’s CHMP has given the nod to Sanofi’s Aubagio and Biogen Idec’s Tecfidera for multiple sclerosis, setting the scene for a European three-way battle with Novartis’ Gilenya in the coming months.

More from Europe

More from Geography